Huiping Qiang

494 total citations · 1 hit paper
20 papers, 362 citations indexed

About

Huiping Qiang is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Huiping Qiang has authored 20 papers receiving a total of 362 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 17 papers in Pulmonary and Respiratory Medicine and 3 papers in Molecular Biology. Recurrent topics in Huiping Qiang's work include Lung Cancer Treatments and Mutations (14 papers), Lung Cancer Research Studies (12 papers) and Cancer Immunotherapy and Biomarkers (11 papers). Huiping Qiang is often cited by papers focused on Lung Cancer Treatments and Mutations (14 papers), Lung Cancer Research Studies (12 papers) and Cancer Immunotherapy and Biomarkers (11 papers). Huiping Qiang collaborates with scholars based in China, Italy and South Korea. Huiping Qiang's co-authors include Jialin Qian, Qing Chang, Yanwei Zhang, Baohui Han, Tianqing Chu, Runbo Zhong, Tianqing Chu, Yuchen Han, Yiming Zhao and Hua Zhong and has published in prestigious journals such as International Journal of Cancer, Frontiers in Immunology and Journal of Thoracic Oncology.

In The Last Decade

Huiping Qiang

19 papers receiving 360 citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Phase 1b Study of Sintilimab Plus Anlotinib as First-line Therapy in Patients With Advanced NSCLC

2021 174 citations Tianqing Chu, Runbo Zhong et al. Journal of Thoracic Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Huiping Qiang China	9	288	194	61	40	38	20	362
Qing Chang China	7	239 0.8×	179 0.9×	55 0.9×	30 0.8×	29 0.8×	21	308
Keita Uchino Japan	12	215 0.7×	151 0.8×	86 1.4×	46 1.1×	59 1.6×	40	357
Giulia Grizzi Italy	12	262 0.9×	185 1.0×	82 1.3×	30 0.8×	41 1.1×	24	370
Yoshiro Nakahara Japan	12	282 1.0×	255 1.3×	55 0.9×	44 1.1×	23 0.6×	42	414
Rui Kitadai Japan	10	213 0.7×	161 0.8×	35 0.6×	24 0.6×	28 0.7×	27	296
T-E. Ciuleanu Romania	11	266 0.9×	240 1.2×	57 0.9×	32 0.8×	29 0.8×	47	345
Hsiang‐Fong Kao Taiwan	8	208 0.7×	108 0.6×	126 2.1×	59 1.5×	39 1.0×	28	372
Silvana Acquafredda Italy	6	159 0.6×	94 0.5×	42 0.7×	43 1.1×	24 0.6×	8	237
Linpeng Zheng China	10	207 0.7×	150 0.8×	77 1.3×	37 0.9×	23 0.6×	17	304
Yueyun Chen China	9	170 0.6×	108 0.6×	71 1.2×	62 1.6×	64 1.7×	27	301

Countries citing papers authored by Huiping Qiang

Since Specialization

Citations

This map shows the geographic impact of Huiping Qiang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Huiping Qiang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Huiping Qiang more than expected).

Fields of papers citing papers by Huiping Qiang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Huiping Qiang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Huiping Qiang. The network helps show where Huiping Qiang may publish in the future.

Co-authorship network of co-authors of Huiping Qiang

This figure shows the co-authorship network connecting the top 25 collaborators of Huiping Qiang. A scholar is included among the top collaborators of Huiping Qiang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Huiping Qiang. Huiping Qiang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Qiang, Huiping, Yao Zhang, Jingwen Li, et al.. (2025). Efficacy of first-line chemotherapy combined with immunotherapy or anti-angiogenic therapy in advanced KRAS-mutant non-small cell lung cancer. Translational Oncology. 53. 102317–102317. 4 indexed citations

Wang, Yue, Rong Qiao, Yao Zhang, et al.. (2025). Synthetic Lethal Co-Mutations in DNA Damage Response Pathways Predict Response to Immunotherapy in Pan-Cancer. JCO Precision Oncology. 9(9). e2500035–e2500035. 1 indexed citations

Xu, Yingqi, et al.. (2024). Impact of PD-L1 expression on the efficacy of first-line crizotinib in advanced ROS1-rearranged NSCLC. Lung Cancer. 194. 107892–107892. 1 indexed citations

Chang, Qing, Jiaqi Li, Yan Zhu, et al.. (2024). Neoadjuvant immunology therapy in patients with non-small cell lung cancer and chronic obstructive pulmonary disease. Journal of Thoracic Disease. 16(11). 7546–7560.

Li, Jiaqi, Ruiying Zhao, Huiping Qiang, et al.. (2024). Anti-angiogenic therapy or immunotherapy? A real-world study of patients with advanced non-small cell lung cancer with EGFR/HER2 exon 20 insertion mutations. Frontiers in Oncology. 14. 1357231–1357231. 4 indexed citations

Lü, Jun, Huiping Qiang, Mingfang Lu, et al.. (2023). Anlotinib Combined with Anti‐PD1 Potentiates Anti‐Tumor Immunity via Immunogenic Cell Death and Macrophage Reprogramming. Advanced Therapeutics. 6(11). 5 indexed citations

Qiang, Huiping, Jiaqi Li, Qing Chang, et al.. (2022). Mining GEO and TCGA Database for Immune Microenvironment of Lung Squamous Cell Carcinoma Patients With or Without Chemotherapy. Frontiers in Oncology. 12. 835225–835225. 8 indexed citations

Shen, Yinchen, Jiaqi Li, Huiping Qiang, et al.. (2022). A retrospective study for prognostic significance of type II diabetes mellitus and hemoglobin A1c levels in non-small cell lung cancer patients treated with pembrolizumab. Translational Lung Cancer Research. 11(8). 1619–1630. 10 indexed citations

Qiang, Huiping, et al.. (2022). Atorvastatin suppressed proliferation and facilitated apoptosis of A549 cells through mediating recruitment of Fas and CD59 in lipid raft. Tropical Journal of Pharmaceutical Research. 21(2). 237–244. 1 indexed citations

10.

Li, Jiaqi, Ying‐Jie Chen, Fan Hu, et al.. (2022). Comparison of the efficacy and safety in the treatment strategies between chemotherapy combined with antiangiogenic and with immune checkpoint inhibitors in advanced non-small cell lung cancer patients with negative PD-L1 expression: A network meta-analysis. Frontiers in Oncology. 12. 1001503–1001503. 2 indexed citations

11.

Qiang, Huiping, Yinchen Shen, Jiaqi Li, et al.. (2022). Pembrolizumab monotherapy or combination therapy for bone metastases in advanced non-small cell lung cancer: a real-world retrospective study. Translational Lung Cancer Research. 11(1). 87–99. 18 indexed citations

12.

Fan, Peng, Huiping Qiang, Zhenhua Liu, et al.. (2022). Effective low-dose Anlotinib induces long-term tumor vascular normalization and improves anti-PD-1 therapy. Frontiers in Immunology. 13. 937924–937924. 25 indexed citations

13.

Su, Chunxia, Juan Zhou, Huiping Qiang, et al.. (2022). Special issue “The advance of solid tumor research in China”: Real‐world clinical outcomes of alectinib for advanced nonsmall‐cell lung cancer patients with ALK fusion in China. International Journal of Cancer. 152(1). 15–23. 2 indexed citations

14.

Chang, Qing, Huiping Qiang, Jialin Qian, et al.. (2021). Epidermal Growth Factor Receptor Mutation Status and Response to Tyrosine Kinase Inhibitors in Advanced Chinese Female Lung Squamous Cell Carcinoma: A Retrospective Study. Frontiers in Oncology. 11. 652560–652560. 12 indexed citations

15.

Chu, Tianqing, Runbo Zhong, Hua Zhong, et al.. (2021). Phase 1b Study of Sintilimab Plus Anlotinib as First-line Therapy in Patients With Advanced NSCLC. Journal of Thoracic Oncology. 16(4). 643–652. 174 indexed citations breakdown →

16.

Qiang, Huiping, Xing Li, Jing Zhao, et al.. (2021). Treatment efficacy of HER2-mutant lung adenocarcinoma by immune checkpoint inhibitors: a multicenter retrospective study. Cancer Immunology Immunotherapy. 71(7). 1625–1631. 14 indexed citations

17.

Chang, Qing, Jianlin Xu, Huiping Qiang, et al.. (2020). EGFR Tyrosine Kinase Inhibitor (TKI) Combined With Concurrent or Sequential Chemotherapy for Patients With Advanced Lung Cancer and Gradual Progression After First-Line EGFR-TKI Therapy: A Randomized Controlled Study. Clinical Lung Cancer. 22(3). e395–e404. 9 indexed citations

18.

Feng, Hui, Huiping Qiang, Qing Chang, et al.. (2020). Clinical characteristics and prognostic factors of surgically resected combined small cell lung cancer: a retrospective study. Lung Cancer. 146. 244–251. 15 indexed citations

19.

Qiang, Huiping, Qing Chang, Jianlin Xu, et al.. (2020). New advances in antiangiogenic combination therapeutic strategies for advanced non-small cell lung cancer. Journal of Cancer Research and Clinical Oncology. 146(3). 631–645. 55 indexed citations

20.

Chang, Qing, Yanwei Zhang, Jianlin Xu, et al.. (2019). First‐line pemetrexed/carboplatin or cisplatin/bevacizumab compared with paclitaxel/carboplatin/bevacizumab in patients with advanced non‐squamous non‐small cell lung cancer with wild‐type driver genes: A real‐world study in China. Thoracic Cancer. 10(5). 1043–1050. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact